Abstract

ABSTRACTThe association between polymorphism of CC chemokine ligand 5 (CCL5) and cancer has been reported in several studies, however, there is no data in papillary thyroid cancer (PTC). Objectives: The aim of this study was to investigate whether a promoter single nucleotide polymorphisms (SNP) in CCL5 contributes to the development of PTC and assess the relationships between the CCL5 SNP and the cliniopathologic characteristics of PTC. Methods: One promoter SNP (rs2107538, –281C/T) in CCL5 was genotyped using direct sequencing in 93 PTC patients and 212 healthy controls. Genetic data were analyzed using SNPStats, Helixtree, and SNPAnalyzer. PTC patients were dichotomized and compared with respect to cliniopathologic characteristics of PTC. Results: An association was evident between PTC and SNP (rs2107538) in CCL5 [codominant model 2 (T/T vs. C/C), OR = 2.74, 95% CI = 1.18–6.37, p = .019; dominant model, OR = 2.25, 95% CI = 1.01–5.03, p = .049; recessive model, OR = 1.73, 95% CI = 1.06–2.82, p = .030]. When the genetic relationships between SNP and subgroups of PTC patients were assessed, SNP rs2107538 in CCL5 was not associated with any clinicopathologic characteristics of PTC. Conclusions: SNP in the CCL5 -281 promoter gene could increase the risk of developing PTC in Koreans.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.